1,5-Benzodiazepine inhibitors of HCV NS5B polymerase.
McGowan, D., Nyanguile, O., Cummings, M.D., Vendeville, S., Vandyck, K., Van den Broeck, W., Boutton, C.W., De Bondt, H., Quirynen, L., Amssoms, K., Bonfanti, J.F., Last, S., Rombauts, K., Tahri, A., Hu, L., Delouvroy, F., Vermeiren, K., Vandercruyssen, G., Van der Helm, L., Cleiren, E., Mostmans, W., Lory, P., Pille, G., Van Emelen, K., Fanning, G., Pauwels, F., Lin, T.I., Simmen, K., Raboisson, P.(2009) Bioorg Med Chem Lett 19: 2492-2496
- PubMed: 19342234 
- DOI: https://doi.org/10.1016/j.bmcl.2009.03.035
- Primary Citation of Related Structures:  
3GOL - PubMed Abstract: 
Optimization through parallel synthesis of a novel series of hepatitis C virus (HCV) NS5B polymerase inhibitors led to the identification of (R)-11-(4-benzyloxy-2-fluorophenyl)-6-hydroxy-3,3-dimethyl-10-(6-methylpyridine-2-carbonyl)-2,3,4,5,10,11-hexahydro-dibenzo[b,e][1,4]diazepin-1-one 11zc and (R)-11-(4-benzyloxy-2-fluorophenyl)-6-hydroxy-3,3-dimethyl-10-(2,5-dimethyloxazol-4-carbonyl)-2,3,4,5,10,11-hexahydro-dibenzo[b,e][1,4]diazepin-1-one 11zk as potent (replicon EC(50)=400nM and 270nM, respectively) and selective (CC(50)>20muM) inhibitors of HCV replication. These data warrant further lead-optimization efforts.
Organizational Affiliation: 
Tibotec BVBA, Gen. De Wittelaan L11 B3, B-2800 Mechelen, Belgium.